Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Sell
28
RXST Quote, Financials, Valuation and Earnings
Last price:
$15.86
Seasonality move
:
30.72%
Day range:
$14.90 - $16.03
52-week range:
$13.50 - $66.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.40x
P/B ratio:
2.28x
Volume:
1.5M
Avg. volume:
1.2M
1-year change:
-73.42%
Market cap:
$641.8M
Revenue:
$139.9M
EPS (TTM):
-$0.72
Analysts' Opinion
-
Consensus RatingRxSight has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.36, RxSight has an estimated upside of 53.71% from its current price of $15.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $15.85.
Fair Value
-
According to the consensus of 7 analysts, RxSight has 53.71% upside to fair value with a price target of $24.36 per share.
RXST vs. S&P 500
-
Over the past 5 trading days, RxSight has overperformed the S&P 500 by 3.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
RxSight does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
RxSight has grown year-over-year revenues for 0 quarters straight. In the most recent quarter RxSight reported revenues of $40.2M.
Earnings Growth
-
RxSight has grown year-over-year earnings for 0 quarters straight. In the most recent quarter RxSight reported earnings per share of -$0.15.
Enterprise value:
404.6M
EV / Invested capital:
--
Price / LTM sales:
4.40x
EV / EBIT:
--
EV / Revenue:
2.89x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-18.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$98.9M
Return On Assets:
-10.56%
Net Income Margin (TTM):
-19.62%
Return On Equity:
-11.86%
Return On Invested Capital:
-11.86%
Operating Margin:
-21.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $49M | $89.1M | $139.9M | $28.6M | $40.2M | |
| Gross Profit | $21.3M | $53.8M | $98.9M | $17.7M | $28.8M | |
| Operating Income | -$63.3M | -$50.1M | -$36.9M | -$10.9M | -$8.6M | |
| EBITDA | -$57.8M | -$41M | -$23.8M | -$8.1M | -$5.4M | |
| Diluted EPS | -$2.42 | -$1.42 | -$0.72 | -$0.25 | -$0.15 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $81.5M | $176.3M | $134.6M | $168.4M | $293.8M | |
| Total Assets | $100.7M | $192.7M | $150.2M | $182.6M | $318.6M | |
| Current Liabilities | $11.6M | $11.1M | $17.2M | $20.9M | $25.9M | |
| Total Liabilities | $398.2M | $54.5M | $60.3M | $22.2M | $37.3M | |
| Total Equity | -$297.5M | $138.2M | $89.9M | $160.4M | $281.2M | |
| Total Debt | $24.4M | $39.8M | $40.2M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$58.9M | -$41.6M | -$16.9M | -$8.3M | -$4.3M | |
| Cash From Investing | $40M | -$22.1M | -$99.3M | $4.6M | $1.3M | |
| Cash From Financing | $6.3M | $61.5M | $123.3M | $3.6M | $3M | |
| Free Cash Flow | -$61.2M | -$46.4M | -$22.4M | -$9.9M | -$5.1M | |
RXST
Sector
Market Cap
$641.8M
$35.8M
Price % of 52-Week High
23.82%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
-9.28%
-0.81%
1-Year Price Total Return
-73.42%
-38.89%
Beta (5-Year)
--
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.94
200-day SMA
Sell
Level
$38.83
Bollinger Bands (100)
Sell
Level
20.09 - 35.99
Chaikin Money Flow
Sell
Level
-1.1M
20-day SMA
Buy
Level
$14.88
Relative Strength Index (RSI14)
Sell
Level
40.46
ADX Line
Sell
Level
41.37
Williams %R
Sell
Level
-7.8125
50-day SMA
Sell
Level
$21.67
MACD (12, 26)
Sell
Level
-1.96
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
6.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (20.774)
Buy
CA Score
(Annual)
Level (1.0115)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.5464)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Stock Forecast FAQ
In the current month, RXST has received 3 Buy ratings 4 Hold ratings, and 0 Sell ratings. The RXST average analyst price target in the past 3 months is $24.36.
-
Where Will RxSight Stock Be In 1 Year?
According to analysts, the consensus estimate is that RxSight share price will rise to $24.36 per share over the next 12 months.
-
What Do Analysts Say About RxSight?
Analysts are divided on their view about RxSight share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that RxSight is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is RxSight's Price Target?
The price target for RxSight over the next 1-year time period is forecast to be $24.36 according to 7 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is RXST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for RxSight is a Hold. 4 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RXST?
You can purchase shares of RxSight via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase RxSight shares.
-
What Is The RxSight Share Price Today?
RxSight was last trading at $15.86 per share. This represents the most recent stock quote for RxSight. Yesterday, RxSight closed at $15.85 per share.
-
How To Buy RxSight Stock Online?
In order to purchase RxSight stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Is Adobe Stock a Bargain With AI Tools Driving Growth?
The share price of American computer software company Adobe (NASDAQ:ADBE)…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
